4) Page 15, line 51: had the HIGHEST (possibly the missing word?) AUC 5) Interestingly, TM-related costs varied according to insurance type. It would be helpful providing details on "Cadre" and "Medical" insurance (just 1-2 lines on introduction or discussion?) 6) "Clinical guidelines" which guided the selection of the TM are mentioned (Page 8; Page 14 line 42). In the setting of lung cancer, currently available serum tumor markers lack sensitivity/specificity for early cancer and malignancy: this should be reminded in the text. Please provide references of the "clinical guidelines" used. Furthermore, it may be useful citing studies on the LC biomarkers selected (e.g. Tumour Biol. 2003; 24(4):209-218 ---Respir Med. 2004; 98(4) 
VERSION 1 -AUTHOR RESPONSE
Responses to the comments of Reviewer 1 (Angelo De Lauretis)
General comment: This manuscript focuses on an important issue of modern medicine: providing high-level and evidence based health service while controlling costs in the resource-limited reality. The Authors also highlight ethical issues raised by "unnecessary" diagnosis, although the burden of this problem may change widely according to difference in society and general social understanding. The excessive use of tumor marked in cancer screening and early stage of cancer diagnosis is a well known problem.
Response: Thank you for taking the time to review our paper and provide us with constructive comments that have helped us to improve our manuscript. We are pleased that you consider our manuscript to focus on an important issue and are delighted with your overall positive assessment of our work. Response: Thank you for these helpful recommendations. We have revised the Results and Discussion sections of the manuscript, including the parts on pages 14, 15 and 17 that you highlighted in your comment, in order to avoid unnecessary duplication of information. We now believe that the paper is easier to read and that the main messages are more clearly presented. We refer you to the revised manuscript for further details of the changes made.
Comment 2: Page 9, line 6: "4 markers were selected as the initial screening indicator of COPD and LC": lung tumor markers are not used for COPD diagnosis or screening, please amend.
Response: We apologize for this inadvertent error, and of course agree that lung tumor markers are not used for the diagnosis or screening of COPD. We have now corrected this text.
Materials and Methods, lines 148-152: "CEA is a tumor marker associated with the severity of COPD18. CYFRA211, NSE, and SCC are markers relatively sensitive for non-small cell lung cancer, small cell lung cancer, and squamous cell lung carcinoma, respectively18-20. Therefore, the above four markers were selected as the initial screening indicators."
Comment 3: ROC/Youden index/linear regression analysis have been used, but not mentioned in the statistical analysis section (page 9), please add those.
Response: Thank you for bringing this important omission to our attention. We have included new text in the Materials and Methods section to briefly describe the methodology used for these analyses.
Materials and Methods, lines 168-173: "The associations of various parameters (TM expense, examination expense and hospitalization expense) with the number of TMs, age, year of discharge, number of diagnoses, and hospital stay were assessed by linear regression analysis. The performance levels of the TMs were determined by calculating the areas under the receiver operating characteristic (ROC) curves (AUCs) as well as Youden index values, sensitivities and specificities." Response: Thank you for pointing out this inadvertent error, the missing word was indeed "highest". The sentence has been corrected.
Discussion, lines 293-294: "The expert committee recommended using CEA+CYFRA211+SCC+NSE as it had the highest AUC (0.813)."
Comment 5: Interestingly, TM-related costs varied according to insurance type. It would be helpful providing details on "Cadre" and "Medical" insurance (just 1-2 lines on introduction or discussion?).
